co.don Aktiengesellschaft: FOCUS Special: co.don AG on the list of growth champions again in 2017
FOCUS Special: co.don AG on the list of growth champions again in 2017
- Eighth place in the category Chemistry and Pharma
- Second year co.don included in prestigious list of growth companies
Teltow/Germany, 17 November 2016 - co.don AG has been included in the FOCUS list of Growth Champions 2017.
Growth Champions compiles a list of the 500 German companies with the highest revenue growth in the past four years. And co.don AG comes in eighth place in the category Chemistry and Pharma.
Dirk Hessel, CEO of co.don AG: "Our aim is to apply the regenerative therapy options from co.don to defer joint replacement or ideally to avoid it altogether in order to maintain everyday routines and quality of life. We are delighted that FOCUS has again selected co.don as a growth champion. This distinction is due to the performance of all our staff, who I would like to thank sincerely on behalf of the Executive Board. To date we have only operated in the German market. For autumn next year we are expecting EU marketing authorisation for our main product. So co.don AG's greatest growth potential is still ahead of us."
About co.don(R) AG: Berlin-based co.don AG develops, produces and markets in Germany autologous cell therapies for the minimally invasive repair of cartilage damage to joints following traumatic or degenerative defects. co.don condrosphere(R) is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). co.don condrosphere(R) has been approved by the German federal agency PEI in accordance with Section 4b of the German Pharmaceuticals Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain European marketing authorisation. co.don condrosphere(R) has been used for more than 10 years in over 120 clinics to treat more than 10,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007 and for the treatment of vertebral joints since 2008. The shares in co.don AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO).
Further information can be found at www.ihre-zellzuechter.de or www.codon.de
Press contact Matthias Meißner, M.A. Corporate communications / IR / PR Tel. +49 (0)30 240352330 Fax +49 (0)30 240352309 Email: email@example.com
17.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language: English Company: co.don Aktiengesellschaft Warthestraße 21 14513 Teltow Germany Phone: 03328 43460 Fax: 03328 434643 E-mail: firstname.lastname@example.org Internet: www.codon.de ISIN: DE000A1K0227 WKN: A1K022 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange End of News DGAP News Service